Assessing the reporting of harms in systematic reviews focused on platelet-rich plasma therapy: a cross-sectional analysis.
Regen Med
; 18(7): 531-542, 2023 07.
Article
en En
| MEDLINE
| ID: mdl-37340904
This study looked at how well the negative effects (harms) of platelet-rich plasma therapy are reported in systematic reviews (SRs). The researchers carefully reviewed and extracted data of SRs from different databases. They found that less than 50% of the SRs reported the harms associated with platelet rich plasma therapy. The researchers also used a tool called AMSTAR to assess the value of each of the SRs, and most were found to be 'critically low' reviews. In conclusion, this study highlights the importance of platelet rich plasma therapy negative effect reporting by SRs.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Estudios Transversales
Tipo de estudio:
Observational_studies
/
Prevalence_studies
/
Risk_factors_studies
/
Systematic_reviews
Idioma:
En
Revista:
Regen Med
Año:
2023
Tipo del documento:
Article
País de afiliación:
Estados Unidos